Drug Trial Radar · NCT07811999
Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
308
Planned (sponsor's estimate)
Start
Sep 22, 2026
Primary completion
Jan 14, 2027
Study completion Jan 14, 2027
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Sep 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to evaluate the relative bioavailability of romosozumab administered as a single 2.34 mL subcutaneous (SC) injection from a prefilled syringe (PFS) or 2 x 1.17 mL SC injections from PFS in healthy participants.
Conditions
- Healthy Participants
Interventions
RomosozumabDrug
Romosozumab will be administered via SC injection using a PFS.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUCinf) of romosozumabTime frame: Up to Day 85
- Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) of romosozumabTime frame: Up to Day 85
- Maximum Observed Serum Concentration (Cmax) of romosozumabTime frame: Up to Day 85
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
QPS Miami
Miami, Florida · Recruiting
Fortrea Clinical Research Unit Limited - Leeds
Leeds, LDS, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.